Previous Close | 75.87 |
1-Year Change | 40.53% |
6-Months Change | 32.87% |
3-Months Change | 19.93% |
Moving Avg (50d) | 68.99 |
Moving Avg (200d) | 61.771 |
ESG Rating | - |
Exchange | NASDAQ |
Market Cap. | 17.0B |
Beta (3-Years) | 0.51 |
Revenue Growth (ttm) | 8.35% |
Net Profit Margin (ttm) | 11.78% |
Return On Assets (ttm) | 6.65% |
EPS (ttm) | 1.88 |
PE Ratio (ttm) | 40.36 |
Dividend Yield | % |
Disclaimer - Please note that the use of AI to analyse contents may occasionally generate incorrect information.
Our cutting-edge algorithms employ macroeconomic data, fundamental and technical analysis indicators to accurately predict the optimal position for short-term trading
By harnessing these signals, we power our asset allocation tools, backtesting tool and portfolio management process, ensuring maximum returns for your investments.
Sector: | Health Care |
Industry: | Biotechnology |
Country: | United States |
Incyte Corporation is an American multinational pharmaceutical company with headquarters in Wilmington, Delaware, and Morges, Switzerland. The company was created in 2002 through the merger of Incyte Pharmaceuticals, founded in Palo Alto, California in 1991 and Incyte Genomics, Inc. of Delaware. The company currently operates manufacturing and R&D locations in North America, Europe, and Asia. Incyte... Wikipedia